CovidChloroV1, Main, Corpus, bibRecord, 001976

Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19.

Identifieur interne : 001976 ( Main/Corpus ); précédent : 001975; suivant : 001977

Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19.

Auteurs : Tony Y. Zhang ; Boyu Zhong

Source :

Medicine in drug discovery [ 2590-0986 ] ; 2020.

RBID : pubmed:32292908

Abstract

This paper provides an overview of the current global market and manufacturing landscape for hydroxychloroquine (HCQ). The capacity and capabilities of global producers to meet the potential demand for treating patients inflicted with COVID-19 by the novel corona virus SARS-CoV-2, should HCQ's efficacy be established by more definitive clinical trials, is also assessed. Given the large existing manufacturing base and abundance of raw materials for HCQ, the supply challenge can be met with considerable efforts and international cooperation. Preemptive and coordinated emergency efforts among global governments, regulatory agencies, chemical and pharmaceutical industries are imperative for meeting the potential surge in demand.

DOI: 10.1016/j.medidd.2020.100036
PubMed: 32292908
PubMed Central: PMC7144509

Links to Exploration step

pubmed:32292908

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19.</title>
<author><name sortKey="Zhang, Tony Y" sort="Zhang, Tony Y" uniqKey="Zhang T" first="Tony Y" last="Zhang">Tony Y. Zhang</name>
<affiliation><nlm:affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhong, Boyu" sort="Zhong, Boyu" uniqKey="Zhong B" first="Boyu" last="Zhong">Boyu Zhong</name>
<affiliation><nlm:affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32292908</idno>
<idno type="pmid">32292908</idno>
<idno type="doi">10.1016/j.medidd.2020.100036</idno>
<idno type="pmc">PMC7144509</idno>
<idno type="wicri:Area/Main/Corpus">001976</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001976</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19.</title>
<author><name sortKey="Zhang, Tony Y" sort="Zhang, Tony Y" uniqKey="Zhang T" first="Tony Y" last="Zhang">Tony Y. Zhang</name>
<affiliation><nlm:affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhong, Boyu" sort="Zhong, Boyu" uniqKey="Zhong B" first="Boyu" last="Zhong">Boyu Zhong</name>
<affiliation><nlm:affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Medicine in drug discovery</title>
<idno type="eISSN">2590-0986</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This paper provides an overview of the current global market and manufacturing landscape for hydroxychloroquine (HCQ). The capacity and capabilities of global producers to meet the potential demand for treating patients inflicted with COVID-19 by the novel corona virus SARS-CoV-2, should HCQ's efficacy be established by more definitive clinical trials, is also assessed. Given the large existing manufacturing base and abundance of raw materials for HCQ, the supply challenge can be met with considerable efforts and international cooperation. Preemptive and coordinated emergency efforts among global governments, regulatory agencies, chemical and pharmaceutical industries are imperative for meeting the potential surge in demand.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32292908</PMID>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2590-0986</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>5</Volume>
<PubDate><Year>2020</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Medicine in drug discovery</Title>
<ISOAbbreviation>Med Drug Discov</ISOAbbreviation>
</Journal>
<ArticleTitle>Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>100036</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medidd.2020.100036</ELocationID>
<Abstract><AbstractText>This paper provides an overview of the current global market and manufacturing landscape for hydroxychloroquine (HCQ). The capacity and capabilities of global producers to meet the potential demand for treating patients inflicted with COVID-19 by the novel corona virus SARS-CoV-2, should HCQ's efficacy be established by more definitive clinical trials, is also assessed. Given the large existing manufacturing base and abundance of raw materials for HCQ, the supply challenge can be met with considerable efforts and international cooperation. Preemptive and coordinated emergency efforts among global governments, regulatory agencies, chemical and pharmaceutical industries are imperative for meeting the potential surge in demand.</AbstractText>
<CopyrightInformation>© 2020 The Authors.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Tony Y</ForeName>
<Initials>TY</Initials>
<AffiliationInfo><Affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhong</LastName>
<ForeName>Boyu</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Med Drug Discov</MedlineTA>
<NlmUniqueID>101765689</NlmUniqueID>
<ISSNLinking>2590-0986</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>04</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32292908</ArticleId>
<ArticleId IdType="doi">10.1016/j.medidd.2020.100036</ArticleId>
<ArticleId IdType="pii">S2590-0986(20)30023-3</ArticleId>
<ArticleId IdType="pii">100036</ArticleId>
<ArticleId IdType="pmc">PMC7144509</ArticleId>
</ArticleIdList>
<pmc-dir>pmcsd</pmc-dir>
        <ReferenceList><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001976 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001976 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32292908
   |texte=   Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32292908" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19.

Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki